Industry Standard Research (ISR) announced the release of a new report focused on the impact comparative effectiveness research (CER) is and will have on formulary placement . “US Payers: Comparative Effectiveness Research and formulary decision-making” looks at how US payers view the importance and impact of various study/ data sources such as randomized controlled trials (RCTs) with placebo, RCTs with a comparator, health economics outcomes research, Quality of Life studies, short and long-term head-to-head studies, meta-analysis of data sets, and retrospective observational studies, among others.
“With this research we wanted to answer questions pertaining to how US payers currently and will in the near future make formulary decisions. This research looks at the impact various study types have on formulary decision-making overall and across seven major therapeutic areas: oncology, diabetes, mental health, asthma/ COPD, arthritis, heart disease, and hypertension.” explained Andrew Schafer, President of Industry Standard Research.
One interesting data point from the “US Payers: Comparative Effectiveness Research and formulary decision-making” report is that in the near future formulary decision-makers will be using data from many more sources to make their decisions. Respondents have many strong concerns about the data contained in randomized controlled trials with a placebo.
These reports provide pharmaceutical companies, contract research organizations, marketing, and consulting companies with information they can use to develop pre- and post-approval development and non-interventional studies that can be used to support formulary placement.
“Comparative effectiveness research is going to have an increasingly and major impact on US payer’s formulary decision-making over the next two years. Payers certainly want it and it can provide pharmaceutical companies with a road to product differentiation and reimbursement.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.